CBX7 Knockout ACHN Cell Line

The CBX7 Knockout ACHN Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the ACHN human renal adenocarcinoma cell line, providing a powerful loss-of-function model for dissecting CBX7-mediated epigenetic regulation and tumor biology. This product enables targeted disruption of the CBX7 gene, which encodes a chromodomain-containing transcriptional repressor central to Polycomb group (PcG) protein function. By eliminating CBX7 expression, researchers can interrogate its role in maintaining gene silencing programs and its contribution to cancer cell phenotypes without altering the endogenous chromatin landscape beyond the intended locus.

ACHN cells are a widely employed human male renal cell adenocarcinoma line of epithelial origin, established from a malignant pleural effusion. These adherent cells retain characteristics of renal epithelial cells and serve as a robust in vitro model for studying renal cell carcinoma (RCC) pathogenesis, signal transduction, and therapeutic responses. Their use in drug discovery, migration assays, and cellular signaling experiments is well documented, making them an optimal background for introducing a CBX7 knockout to explore mechanisms specific to renal cancer and beyond.

CBX7 functions as a reader of trimethylated lysine 27 on histone H3 (H3K27me3), a repressive chromatin mark deposited by the PRC2 complex containing EZH2 and SUZ12. Via its chromodomain, CBX7 is recruited to H3K27me3-rich genomic regions where it nucleates PRC1 assembly with core components RING1 and BMI1, thereby enforcing transcriptional repression of key target genes. Prominent among these is the CDKN2A locus, which encodes the tumor suppressors p16(JNK4A) and p14(ARF). CBX7 loss relieves this repression, leading to upregulation of p16 and p14(ARF), engagement of the RB1 pathway, and induction of downstream effectors such as BIM and CCNA2 that drive cell cycle arrest and senescence. CBX7 expression itself is regulated by upstream mitogenic and stress signals through E2F transcription factors, MYC, and TGF-??, while p16 provides feedback control. Thus, CBX7 integrates cues from Polycomb repression, cellular senescence, TGF-??, and Wnt signaling networks to orchestrate proliferation, senescence, and stem cell identity.

In the ACHN renal adenocarcinoma context, CBX7 knockout is particularly informative given the gene’s documented involvement in RCC, prostate cancer, and breast cancer. Aberrant CBX7 expression has been associated with tumor progression and drug resistance, while its loss can trigger senescence programs that limit malignant growth. By introducing a CBX7 disruption, this cell line enables detailed investigation of how CBX7-dependent silencing of CDKN2A and other targets influences renal tumorigenesis, including epithelial-mesenchymal transition, invasiveness, and response to targeted therapies. The model also facilitates studies on crosstalk between PRC1 and PRC2, H3K27me3 dynamics, and TGF-??-driven growth control.

This product is ideally suited for an array of advanced research applications spanning epigenetics, cancer biology, drug resistance, and the tumor microenvironment. Typical experimental approaches include chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) to assess H3K27me3 occupancy at PRC1 target loci, RNA sequencing (RNA-seq) for transcriptome profiling, and quantitative reverse-transcription PCR (RT-qPCR) to validate gene expression changes. Functional outcomes can be measured through cell proliferation assays, cell cycle analysis via flow cytometry, and senescence-associated ??-galactosidase staining. Together, these tools enable mechanistic dissection of CBX7’s role in renal cancer and screening of epigenetic or signaling pathway modulators. For further details, technical support, or custom validation data, please contact Ascent Research.